Literature DB >> 7540469

A unique population of CD34+ cells in cord blood.

M T Nimgaonkar1, R A Roscoe, J Persichetti, W B Rybka, A Winkelstein, E D Ball.   

Abstract

Human umbilical cord blood (CB) is a rich source of hematopoietic stem cells for both research and stem cell transplantation. In clinical studies, it appears that recovery from myeloablative therapy using CB requires significantly fewer cells than a typical allogeneic marrow transplant. This suggests that CB may be enriched for early hematopoietic progenitors. The present studies were undertaken to determine the presence of CD34+ cells in CB with the phenotypic characteristics of multipotential stem cells. In 22 CB harvests, the average percentage of CD34+ cells was 1.33 +/- 0.21% (SE), a value similar to that in adult normal bone marrows (BM). However, the distribution of CD34+ cells was distinctly different from either BM or granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cell harvests. CB contained a defined population of brightly staining CD34+ cells with low side scatter. These CD34 (bright) cells comprised a mean of 14.5 +/- 2.5% of the CB CD34+ cells, whereas < 1% of BM CD34+ cells has been shown to be CD34- bright. Eighty-five to ninety percent were negative for three antigens expressed at an early stage of stem cell maturation: CD38, HLA-DR and LFA-1. Fifty-five percent of these CD34 (bright) cells did not express the CD45RA isoform, an additional marker of immaturity. The antigen-bright cells also lacked lineage-specific antigens including CD33, CD56, CD19, CD10 and CD7 as well as CD71. Approximately 46% were Thy-1+, and 40% expressed c-kit receptors. These data suggest that, by phenotypic criteria, CB may be a particularly enriched source of primitive hematopoietic precursors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540469     DOI: 10.1002/stem.5530130207

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

Review 1.  Cell Therapy for Ischemic Stroke: How to Turn a Promising Preclinical Research into a Successful Clinical Story.

Authors:  Gabrielle Mangin; Nathalie Kubis
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

Review 2.  Cord blood transplant: current and future issues.

Authors:  S Inoue
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

3.  Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells.

Authors:  Aditi Bapat; Nakia Keita; Shalini Sharma
Journal:  J Vis Exp       Date:  2019-08-09       Impact factor: 1.355

4.  Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells.

Authors:  Jose Perdomo; Feng Yan; Halina H L Leung; Beng H Chong
Journal:  J Vis Exp       Date:  2017-12-27       Impact factor: 1.355

5.  Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.

Authors:  Sherin Bakhashab; Fahad W Ahmed; Hans-Juergen Schulten; Ayat Bashir; Sajjad Karim; Abdulrahman L Al-Malki; Mamdooh A Gari; Adel M Abuzenadah; Adeel G Chaudhary; Mohammed H Alqahtani; Sahira Lary; Farid Ahmed; Jolanta U Weaver
Journal:  Cardiovasc Diabetol       Date:  2016-02-09       Impact factor: 9.951

6.  Molecular transitions in early progenitors during human cord blood hematopoiesis.

Authors:  Shiwei Zheng; Efthymia Papalexi; Andrew Butler; William Stephenson; Rahul Satija
Journal:  Mol Syst Biol       Date:  2018-03-15       Impact factor: 11.429

7.  Preeclampsia in pregnancy affecting the stemness and differentiation potency of haematopoietic stem cell of the umbilical cord blood.

Authors:  Fazlina Nordin; Mohd Razif Mohd Idris; Zaleha Abdullah Mahdy; S Fadilah Abd Wahid
Journal:  BMC Pregnancy Childbirth       Date:  2020-07-10       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.